

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Young <i>et al.</i>	Confirmation No.:	3135
Serial No.:	10/657,363	Art Unit:	1648
Filed:	September 8, 2003	Examiner:	Hill, Myron G.
For:	ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES	Attorney Docket No.:	10271-159-999 (CAM: 209073-999157)

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

MEDIMMUNE, LLC is the assignee of the entire right, title and interest in and to the above-identified application, which is a continuation of U.S. Serial No. 09/771,415 (now U.S. Patent No. 6,656,467), by virtue of:

(1) an assignment of U.S. Serial No. 09/771,415 (now U.S. Patent No. 6,656,467) and continuing applications from James F. Young, Scott Koenig, and Leslie S. Johnson to MedImmune, Inc., which was recorded on October 21, 2002 at reel 013402 frame 0673;

(2) an assignment of U.S. Serial No. 09/771,415 (now U.S. Patent No. 6,656,467) and continuing applications from William D. Huse, Herren Wu, and Jeffrey D. Watkins to Applied Molecular Evolution, Inc., which was recorded on October 21, 2002 at reel 013402 frame 0257;

(3) a Certificate of Conversion and Certificate of Formation from the Secretary of State of the State of Delaware evidencing the name change of MedImmune, Inc. to MEDIMMUNE, LLC, which is submitted for recordation herewith (a copy of which is attached); and

(4) an assignment of the above-identified application from Applied Molecular Evolution, Inc. to MedImmune, LLC, which was recorded on April 27, 2010 at reel 024297 frame 0696.<sup>1</sup>

<sup>1</sup>. This assignment was initially recorded in connection with the above-identified application on April 26, 2010 at reel 024290 frame 0704, but the Assignor, "Applied Molecular Evolution, Inc.", was inadvertently listed as

MEDIMMUNE, LLC is the assignee of the entire right, title and interest in and to U.S. Serial No. 09/771,415 (now U.S. Patent No. 6,656,467), by virtue of:

(1) an assignment of U.S. Patent No. 6,656,467 from James F. Young, Scott Koenig, and Leslie S. Johnson to MedImmune, Inc., which was recorded on October 21, 2002 at reel 013402 frame 0673;

(2) an assignment of U.S. Patent No. 6,656,467 from William D. Huse, Herren Wu, and Jeffrey D. Watkins to Applied Molecular Evolution, Inc., which was recorded on October 21, 2002 at reel 013402 frame 0257;

(3) an assignment of U.S. Patent No. 6,656,467 from Applied Molecular Evolution, Inc. to MedImmune, Inc., which was recorded on September 16, 2005 at reel 016999 frame 0427; and

(4) a Certificate of Conversion and Certificate of Formation from the Secretary of State of the State of Delaware evidencing the name change of MedImmune, Inc. to MEDIMMUNE, LLC, which was recorded on April 29, 2009 at reel 022610 frame 0321, for U.S. Patent No. 6,656,467.

MEDIMMUNE, LLC hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of U.S. Patent No. 6,656,467, which issued on December 2, 2003, and hereby agrees that the patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,656,467.

MEDIMMUNE, LLC further agrees that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.

MEDIMMUNE, LLC does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent No. 6,656,467 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

The undersigned hereby confirms that he has reviewed the assignment and, to the best of his

---

"Applied Molecular Evolution" on the Electronic Patent Assignment System forms. A corrective assignment was recorded on April 27, 2010 at reel 024297 frame 0696, which corrected the Assignor's name to "Applied Molecular Evolution, Inc.", as recited on the executed assignment.


knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of MEDIMMUNE, LLC.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 4th day of May 2010.

MEDIMMUNE, LLC

By: \_\_\_\_\_

  
Name: Patrick Scott Alban  
Title: Associate General Counsel, Head of IP  
MedImmune, LLC  
One MedImmune Way  
Gaithersburg, MD 20878

# Delaware

PAGE 1

## *The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CONVERSION OF A DELAWARE CORPORATION UNDER THE NAME OF "MEDIMMUNE, INC." TO A DELAWARE LIMITED LIABILITY COMPANY, CHANGING ITS NAME FROM "MEDIMMUNE, INC." TO "MEDIMMUNE, LLC", FILED IN THIS OFFICE ON THE TWENTY-FIFTH DAY OF MARCH, A.D. 2008, AT 9:31 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF CONVERSION IS THE FIRST DAY OF APRIL, A.D. 2008, AT 12:01 O'CLOCK A.M.

2130616 8100V

080355665

You may verify this certificate online  
at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State  
AUTHENTICATION: 6478252

DATE: 03-26-08

# Delaware

PAGE 2

*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF CERTIFICATE OF FORMATION OF "MEDIMMUNE, LLC" FILED IN THIS OFFICE ON THE TWENTY-FIFTH DAY OF MARCH, A.D. 2008, AT 9:31 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF FORMATION IS THE FIRST DAY OF APRIL, A.D. 2008, AT 12:01 O'CLOCK A.M.

2130616 8100V

080355665

You may verify this certificate online  
at [corp.delaware.gov/authrec.shtml](http://corp.delaware.gov/authrec.shtml)



Harriet Smith Windsor  
Harriet Smith Windsor, Secretary of State  
AUTHENTICATION: 6478252

DATE: 03-26-08

CERTIFICATE OF CONVERSION

CONVERTING

MEDIMMUNE, INC.  
(A Delaware Corporation)

TO

MEDIMMUNE, LLC  
(A Delaware Limited Liability Company)

MedImmune, LLC, the continuing Delaware limited liability company (the "Company"), following the conversion of MedImmune, Inc. (the "Converting Corporation") to the Company, hereby certifies that:

1. Name of Converting Corporation. The name of the Converting Corporation immediately prior to the filing of this Certificate of Conversion was "MedImmune, Inc."

2. Date and Jurisdiction of Organization of Converting Corporation. The date on which, and the jurisdiction where, the Converting Corporation was organized are as follows:

Date

Jurisdiction

June 29, 1987

Delaware

3. Name of Converted Limited Liability Company. The name of the Delaware limited liability company to which the Converting Corporation has been converted and the name set forth in the Certificate of Formation of the Company filed in accordance with Section 18-214(b) of the Delaware Limited Liability Company Act is "MedImmune, LLC."

4. Approval of Conversion. The conversion of the Converting Corporation to the Company has been approved in accordance with the provisions of Section 266 of the Delaware General Corporation Law and Section 18-214 of the Delaware Limited Liability Company Act.

5. Effective Time. This Certificate shall be effective as of 12:01 a.m. on April 1, 2008 after its filing in the Office of the Secretary of the State of Delaware.

*(signature page follows)*

IN WITNESS WHEREOF, the undersigned have duly executed this Certificate of Conversion as of March 25, 2008.

MedImmune, LLC

By: /s/William C. Bertrand

Name: William C. Bertrand, Jr.

Title: Senior Vice President, General  
Counsel and Corporate Secretary

**CERTIFICATE OF FORMATION  
OF  
MEDIMMUNE, LLC**

This Certificate of Formation is being executed as of March 25, 2008 for the purpose of forming a limited liability company pursuant to the Delaware Limited Liability Company Act, 6 Del. C. §§ 18-101 et seq. (the "Delaware LLC Act").

The undersigned, being duly authorized to execute and file this Certificate of Formation, does hereby certify as follows:

1. Name. The name of the limited liability company is MedImmune, LLC (the "Company").

2. Registered Office and Registered Agent. The Company's registered office in the State of Delaware is located at Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The registered agent of the Company for service of process at such address is The Corporation Trust Company.

3. Conversion. The Company has been converted to a Delaware limited liability company pursuant to Section 18-214 of the Delaware LLC Act.

4. Effective Time. This Certificate shall be effective as of 12:01 a.m. on April 1, 2008 after its filing in the Office of the Secretary of the State of the State of Delaware.

IN WITNESS WHEREOF, the undersigned has duly executed this Certificate of Formation as of the day and year first above written.

/s/William C. Bertrand

Name: William C. Bertrand, Jr.  
Title: Senior Vice President, General  
Counsel and Secretary